\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ examination\\ the\\ patient\\â\\€\\™s\\ lungs\\ were\\ clear\\ to\\ auscultation\\.\\ \\ her\\ heart\\ rate\\ was\\ regular\\ without\\ murmurs\\,\\ gallops\\ or\\ rubs\\.\\ \\ neurologic\\ examination\\ was\\ normal\\.\\ \\ her\\ room\\ air\\ resting\\ sao2\\ was\\ 99\\%\\ which\\ quickly\\ fell\\ to\\ 93\\%\\ with\\ ambulation\\.\\ \\ following\\ imaging\\,\\ bronchioaveolar\\ lavage\\ was\\ conducted\\ revealing\\ cryptococcus\\ neoformans\\ on\\ fluid\\ culture\\.\\ \\ cell\\ count\\ 1\\ revealed\\ rbc\\ 386\\,\\ wbc\\ 133\\,\\ neutrophils\\ 9\\,\\ lymphocytes\\ 24\\,\\ and\\ macrophages\\ 67\\.\\ \\ cell\\ count\\ 2\\ revealed\\ rbc\\ 363\\,\\ wbc\\ 199\\,\\ neutrophils\\ 41\\,\\ lymphocytes\\ 24\\,\\ macrophages\\ 33\\,\\ and\\ eosinophils\\ 2\\.\\ culture\\ was\\ negative\\ to\\ all\\ else\\ including\\ aerobic\\ cultures\\,\\ acid\\ fast\\ bacilli\\,\\ and\\ fungal\\ smears\\.\\ \\ subsequent\\ serum\\ labs\\ revealed\\ a\\ negative\\ anca\\,\\ ige\\ 64\\,\\ ldh\\ 586\\,\\ eosinophils\\ 0\\,\\ and\\ negative\\ hiv\\.\\ \\ serum\\ cryptococcal\\ antigen\\ testing\\ was\\ also\\ negative\\.\ \(0\)\
\-\ due\\ to\\ the\\ symptomatic\\ nature\\ of\\ her\\ disease\\,\\ treatment\\ was\\ begun\\ with\\ fluconazol\\ 300\\ mg\\ by\\ mouth\\ daily\\ for\\ 6\\ months\\.\\ \\ her\\ check\\-up\\ 1\\ month\\ later\\ revealed\\ markedly\\ decreased\\ nodular\\ infiltrates\\ on\\ both\\ chest\\ x\\-ray\\ and\\ ct\\.\\ \\ the\\ patient\\ also\\ reported\\ resolution\\ of\\ her\\ cough\\ and\\ overall\\ malaise\\.\ \(0\)\
\-\ chest\\ x\\-ray\\ demonstrated\\ rounded\\ lobular\\ nodules\\ in\\ the\\ left\\ lower\\ lobe\\.\\ \\ ct\\ pulmonary\\ angiogram\\ revealed\\ multiple\\ enhancing\\ left\\ lower\\ lobe\\ masses\\,\\ some\\ with\\ cavitation\\.\ \(0\)\
\-\ cryptococcal\\ pneumonia\ \(0\)\
\-\ 1\\)\\ malignancy\ \(0\)\
\-\ metastatic\\ disease\\:\\ testicular\\,\\ ovarian\\,\\ renal\\,\\ breast\\,\\ melanoma\\ and\\ sarcoma\ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ benign\\:\\ hamartomas\\,\\ papillomatosis\\,\\ bronchogenic\\ cysts\\,\\ benign\\ metastasizing\\ leiomyomatosis\\ \ \(0\)\
\-\ 2\\)\\ infectious\ \(0\)\
\-\ multiple\\ abscesses\ \(1\)\
\-\ septic\\ emboli\ \(22\)\
\-\ granulomatous\\ infections\ \(1\)\
\-\ viral\\:\\ varicella\\,\\ measles\ \(0\)\
\-\ parasitic\\:\\ paragonimus\\ westermani\\ \ \(0\)\
\-\ 3\\)\\ inflammatory\ \(0\)\
\-\ wegener\\â\\€\\™s\\ granulomatosis\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ rheumatoid\\ nodules\ \(0\)\
\-\ a\\ 53\\-year\\-old\\ woman\\ presents\\ to\\ the\\ ed\\ with\\ a\\ three\\ month\\ history\\ of\\ a\\ chronic\\ dry\\ cough\\,\\ malaise\\,\\ and\\ increasing\\ dyspnea\\ on\\ exertion\\.\\ \\ significant\\ medical\\ history\\ included\\ a\\ positive\\ ppd\\ in\\ 1985\\ which\\ was\\ treated\\ with\\ 1\\ year\\ of\\ isoniazid\\.\\ \\ other\\ medical\\ history\\ included\\ hypertension\\ and\\ type\\ ii\\ diabetes\\ mellitus\\.\\ \\ she\\ had\\ immigrated\\ to\\ the\\ united\\ states\\ from\\ the\\ phillipines\\ two\\ decades\\ ago\\.\\ she\\ denied\\ any\\ history\\ of\\ smoking\\ or\\ alcohol\\ use\\.\\ \\ she\\ had\\ also\\ visited\\ the\\ philippines\\ several\\ months\\ ago\\.\ \(0\)\
\-\ the\\ presentation\\ of\\ this\\ patient\\ along\\ with\\ her\\ positive\\ cultures\\ solidifies\\ the\\ diagnosis\\ of\\ cryptococcal\\ pneumonia\\,\\ a\\ rare\\ condition\\ in\\ an\\ otherwise\\ healthy\\ female\\.\\ cryptococcus\\ neoformans\\ is\\ a\\ fungus\\ usually\\ acquired\\ via\\ inhalation\\ of\\ dehydrated\\ yeast\\ cells\\ or\\ basidiospores\\ that\\ has\\ been\\ shown\\ in\\ analysis\\ of\\ soils\\ to\\ be\\ found\\ with\\ pigeon\\ excreta\\.\\ inhalation\\ of\\ the\\ spores\\ is\\ believed\\ to\\ be\\ the\\ primary\\ means\\ of\\ acquisition\\.\\ \\ when\\ considering\\ the\\ prevalence\\ of\\ the\\ disease\\,\\ serologic\\ studies\\ have\\ demonstrated\\ evidence\\ of\\ widespread\\ subclinical\\ infection\\ in\\ individuals\\ without\\ a\\ history\\ of\\ symptomatic\\ infection\\ with\\ most\\ adults\\ having\\ a\\ positive\\ serum\\ antibody\\ to\\ cryptococcus\\ neoformans\\.\\ thus\\,\\ it\\ appears\\ that\\ the\\ subclinical\\ primary\\ infection\\ is\\ common\\ and\\ the\\ vast\\ majority\\ of\\ patients\\ are\\ asymptomatic\\.\\ \\ despite\\ strong\\ serologic\\ evidence\\,\\ symptomatic\\ cryptococcus\\ remains\\ a\\ very\\ rare\\ disease\\ in\\ individuals\\ without\\ impaired\\ immunity\\.\\ \\ an\\ active\\ surveillance\\ conducted\\ in\\ the\\ early\\ 90\\â\\€\\™s\\ in\\ alabama\\ estimated\\ the\\ incidence\\ of\\ active\\ cryptococcus\\ infections\\ at\\ 0\\.84\\ cases\\ per\\ 100\\,000\\ in\\ non\\-hiv\\ individuals\\.\\ \\ however\\,\\ in\\ patients\\ with\\ advanced\\ hiv\\ infections\\ living\\ in\\ san\\ francisco\\ and\\ atlanta\\ in\\ the\\ early\\ 90\\â\\€\\™s\\,\\ the\\ incidence\\ was\\ higher\\ and\\ was\\ estimated\\ to\\ be\\ anywhere\\ from\\ 17\\ to\\ 66\\ cases\\ per\\ 1000\\ individuals\\.\\ \\ other\\ patients\\ who\\ appear\\ to\\ be\\ at\\ increased\\ risk\\ include\\ cancer\\ patients\\ and\\ those\\ individuals\\ receiving\\ organ\\ transplants\\.\\ \\ thus\\,\\ the\\ subsequent\\ course\\ of\\ the\\ infection\\ \\(resolution\\ vs\\.\\ latent\\ infection\\ vs\\.\\ acute\\ infection\\ with\\ or\\ without\\ dissemination\\)\\ appears\\ to\\ be\\ primarily\\ determined\\ by\\ the\\ host\\â\\€\\™s\\ immune\\ status\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cryptococcus\\:\\ 0\\.2567133407908716\ \(0\)\
\-\ individuals\\:\\ 0\\.20101594519923652\ \(0\)\
\-\ the\\:\\ 0\\.17642863837322195\ \(0\)\
\-\ cryptococcal\\:\\ 0\\.17623950821963874\ \(0\)\
\-\ neoformans\\:\\ 0\\.1704232147960397\ \(0\)\
\-\ her\\:\\ 0\\.14410276445027395\ \(0\)\
\-\ infection\\:\\ 0\\.13933148517714616\ \(0\)\
\-\ was\\:\\ 0\\.1339783403694392\ \(0\)\
\-\ of\\:\\ 0\\.12789377251645573\ \(0\)\
\-\ revealed\\:\\ 0\\.12603498397877286\ \(0\)\
\-\ to\\:\\ 0\\.12493940182533797\ \(0\)\
\-\ in\\:\\ 0\\.11476103109074957\ \(0\)\
\-\ hiv\\:\\ 0\\.11405416019527553\ \(0\)\
\-\ serologic\\:\\ 0\\.10815040642352089\ \(0\)\
\-\ subclinical\\:\\ 0\\.10607268319782846\ \(0\)\
\-\ serum\\:\\ 0\\.10341772467537305\ \(0\)\
\-\ and\\:\\ 0\\.10326960244905732\ \(0\)\
\-\ infections\\:\\ 0\\.10182773507213114\ \(0\)\
\-\ inhalation\\:\\ 0\\.09998059206776806\ \(0\)\
\-\ macrophages\\:\\ 0\\.09580016225181139\ \(0\)\
\-\ negative\\:\\ 0\\.09519967665725401\ \(0\)\
\-\ eosinophils\\:\\ 0\\.09493027841821662\ \(0\)\
\-\ neutrophils\\:\\ 0\\.08946520831104438\ \(0\)\
\-\ conducted\\:\\ 0\\.08891498818727413\ \(0\)\
\-\ symptomatic\\:\\ 0\\.0886816856838241\ \(0\)\
\-\ patients\\:\\ 0\\.08650559841100627\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.08645756319557313\ \(0\)\
\-\ malaise\\:\\ 0\\.08517292290435756\ \(0\)\
\-\ without\\:\\ 0\\.08110935987363747\ \(0\)\
\-\ estimated\\:\\ 0\\.07984469175248726\ \(0\)\
\-\ be\\:\\ 0\\.07797433652965732\ \(0\)\
\-\ rbc\\:\\ 0\\.07734149924201518\ \(0\)\
\-\ positive\\:\\ 0\\.07599627321767467\ \(0\)\
\-\ with\\:\\ 0\\.07527658177356408\ \(0\)\
\-\ culture\\:\\ 0\\.07447162556109682\ \(0\)\
\-\ history\\:\\ 0\\.07343762982967862\ \(0\)\
\-\ cultures\\:\\ 0\\.07242030493214753\ \(0\)\
\-\ thus\\:\\ 0\\.07064033515249744\ \(0\)\
\-\ she\\:\\ 0\\.0686529541230375\ \(0\)\
\-\ included\\:\\ 0\\.06648772479188103\ \(0\)\
\-\ incidence\\:\\ 0\\.0661848239249904\ \(0\)\
\-\ disease\\:\\ 0\\.06454835009842508\ \(0\)\
\-\ per\\:\\ 0\\.06381085753633492\ \(0\)\
\-\ count\\:\\ 0\\.0634800796764098\ \(0\)\
\-\ resolution\\:\\ 0\\.06238238442543963\ \(0\)\
\-\ fluconazol\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ paragonimus\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ westermani\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ immigrated\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ visited\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ philippines\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ solidifies\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ basidiospores\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ soils\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ pigeon\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ excreta\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ spores\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ atlanta\\:\\ 0\\.061479037793465696\ \(0\)\
\-\ 90\\:\\ 0\\.061437411142329604\ \(0\)\
\-\ nodules\\:\\ 0\\.06109090050811743\ \(0\)\
\-\ pneumonia\\:\\ 0\\.06068651453752622\ \(0\)\
\-\ bronchioaveolar\\:\\ 0\\.05874650273987957\ \(0\)\
\-\ 586\\:\\ 0\\.05874650273987957\ \(0\)\
\-\ phillipines\\:\\ 0\\.05874650273987957\ \(0\)\
\-\ alabama\\:\\ 0\\.05874650273987957\ \(0\)\
\-\ francisco\\:\\ 0\\.05874650273987957\ \(0\)\
\-\ vs\\:\\ 0\\.05865630112953866\ \(0\)\
\-\ subsequent\\:\\ 0\\.05820697547798113\ \(0\)\
\-\ rare\\:\\ 0\\.05804226644673156\ \(0\)\
\-\ cough\\:\\ 0\\.05740284910058622\ \(0\)\
\-\ active\\:\\ 0\\.057094167182211934\ \(0\)\
\-\ 363\\:\\ 0\\.05680773826534657\ \(0\)\
\-\ leiomyomatosis\\:\\ 0\\.05680773826534657\ \(0\)\
\-\ yeast\\:\\ 0\\.05680773826534657\ \(0\)\
\-\ immunity\\:\\ 0\\.05680773826534657\ \(0\)\
\-\ appears\\:\\ 0\\.05630399098083399\ \(0\)\
\-\ ago\\:\\ 0\\.05625610986004586\ \(0\)\
\-\ early\\:\\ 0\\.0554221209113871\ \(0\)\
\-\ 386\\:\\ 0\\.055303915707610944\ \(0\)\
\-\ bacilli\\:\\ 0\\.055303915707610944\ \(0\)\
\-\ metastasizing\\:\\ 0\\.055303915707610944\ \(0\)\
\-\ 24\\:\\ 0\\.054510182374946425\ \(0\)\
\-\ wbc\\:\\ 0\\.05434326356890259\ \(0\)\
\-\ also\\:\\ 0\\.05424773141271464\ \(0\)\
\-\ ige\\:\\ 0\\.054075203211760445\ \(0\)\
\-\ isoniazid\\:\\ 0\\.054075203211760445\ \(0\)\
\-\ or\\:\\ 0\\.053494811921354385\ \(0\)\
\-\ smears\\:\\ 0\\.05303634159891423\ \(0\)\
\-\ anca\\:\\ 0\\.05303634159891423\ \(0\)\
\-\ benign\\:\\ 0\\.052815760466980416\ \(0\)\
\-\ 199\\:\\ 0\\.05213643873722744\ \(0\)\
\-\ else\\:\\ 0\\.05213643873722744\ \(0\)\
\-\ aerobic\\:\\ 0\\.05213643873722744\ \(0\)\
\-\ measles\\:\\ 0\\.05213643873722744\ \(0\)\
\-\ latent\\:\\ 0\\.05213643873722744\ \(0\)\
\-\ cases\\:\\ 0\\.051714135346569594\ \(0\)\
\-\ 1985\\:\\ 0\\.05134266815817432\ \(0\)\
\-\ transplants\\:\\ 0\\.05134266815817432\ \(0\)\
\-\ varicella\\:\\ 0\\.050632616179491816\ \(0\)\
\-\ dehydrated\\:\\ 0\\.050632616179491816\ \(0\)\
\-\ acquisition\\:\\ 0\\.04999029603388403\ \(0\)\
\-\ dissemination\\:\\ 0\\.04999029603388403\ \(0\)\
\-\ host\\:\\ 0\\.049403903683641316\ \(0\)\
\-\ examination\\:\\ 0\\.04919995860227758\ \(0\)\
\-\ medical\\:\\ 0\\.04886437642174287\ \(0\)\
\-\ begun\\:\\ 0\\.0483650420707951\ \(0\)\
\-\ cavitation\\:\\ 0\\.0483650420707951\ \(0\)\
\-\ sao2\\:\\ 0\\.04790008112590569\ \(0\)\
\-\ lavage\\:\\ 0\\.04790008112590569\ \(0\)\
\-\ san\\:\\ 0\\.04790008112590569\ \(0\)\
\-\ hamartomas\\:\\ 0\\.04746513920910831\ \(0\)\
\-\ papillomatosis\\:\\ 0\\.04746513920910831\ \(0\)\
\-\ primary\\:\\ 0\\.047276835263636637\ \(0\)\
\-\ demonstrated\\:\\ 0\\.04725230655563427\ \(0\)\
\-\ antigen\\:\\ 0\\.047056574080047646\ \(0\)\
\-\ month\\:\\ 0\\.04677087961750656\ \(0\)\
\-\ fungus\\:\\ 0\\.04667136863005519\ \(0\)\
\-\ on\\:\\ 0\\.046442018937254526\ \(0\)\
\-\ vast\\:\\ 0\\.04630699553255154\ \(0\)\
\-\ resting\\:\\ 0\\.04596131665137269\ \(0\)\
\-\ 1000\\:\\ 0\\.04596131665137269\ \(0\)\
\-\ quickly\\:\\ 0\\.0453189965057649\ \(0\)\
\-\ ambulation\\:\\ 0\\.0453189965057649\ \(0\)\
\-\ 133\\:\\ 0\\.0453189965057649\ \(0\)\
\-\ widespread\\:\\ 0\\.04501942449083806\ \(0\)\
\-\ months\\:\\ 0\\.04475409932002882\ \(0\)\
\-\ living\\:\\ 0\\.04473260415552219\ \(0\)\
\-\ anywhere\\:\\ 0\\.04473260415552219\ \(0\)\
\-\ lobe\\:\\ 0\\.04443220888588475\ \(0\)\
\-\ cell\\:\\ 0\\.04398255733949718\ \(0\)\
\-\ 300\\:\\ 0\\.04393883357646908\ \(0\)\
\-\ antibody\\:\\ 0\\.04393883357646908\ \(0\)\
\-\ revealing\\:\\ 0\\.043693742542675974\ \(0\)\
\-\ ppd\\:\\ 0\\.043693742542675974\ \(0\)\
\-\ impaired\\:\\ 0\\.043693742542675974\ \(0\)\
\-\ evidence\\:\\ 0\\.043640830044124924\ \(0\)\
\-\ decades\\:\\ 0\\.0434572529914337\ \(0\)\
\-\ wegener\\:\\ 0\\.04300780243466509\ \(0\)\
\-\ means\\:\\ 0\\.04300780243466509\ \(0\)\
\-\ 93\\:\\ 0\\.04279383968098918\ \(0\)\
\-\ mellitus\\:\\ 0\\.04279383968098918\ \(0\)\
\-\ immune\\:\\ 0\\.04279383968098918\ \(0\)\
\-\ fast\\:\\ 0\\.04238527455192852\ \(0\)\
\-\ infiltrates\\:\\ 0\\.04238527455192852\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.04238527455192852\ \(0\)\
\-\ united\\:\\ 0\\.04200006910193607\ \(0\)\
\-\ prevalence\\:\\ 0\\.04200006910193607\ \(0\)\
\-\ surveillance\\:\\ 0\\.04200006910193607\ \(0\)\
\-\ ldh\\:\\ 0\\.041815420272963706\ \(0\)\
\-\ parasitic\\:\\ 0\\.041815420272963706\ \(0\)\
\-\ considering\\:\\ 0\\.04163569600443241\ \(0\)\
\-\ believed\\:\\ 0\\.04112360717053868\ \(0\)\
\-\ chest\\:\\ 0\\.04058453270943751\ \(0\)\
\-\ dry\\:\\ 0\\.04049624654420044\ \(0\)\
\-\ exertion\\:\\ 0\\.04034812496271893\ \(0\)\
\-\ strong\\:\\ 0\\.04006130462740306\ \(0\)\
\-\ other\\:\\ 0\\.03992833665227529\ \(0\)\
\-\ gallops\\:\\ 0\\.03992234587624363\ \(0\)\
\-\ acid\\:\\ 0\\.03992234587624363\ \(0\)\
\-\ receiving\\:\\ 0\\.03992234587624363\ \(0\)\
\-\ organ\\:\\ 0\\.0395218759561608\ \(0\)\
\-\ lower\\:\\ 0\\.03928902921285658\ \(0\)\
\-\ lobular\\:\\ 0\\.039022443014556846\ \(0\)\
\-\ abscesses\\:\\ 0\\.039022443014556846\ \(0\)\
\-\ rubs\\:\\ 0\\.03867074962100759\ \(0\)\
\-\ had\\:\\ 0\\.03830762632668544\ \(0\)\
\-\ mouth\\:\\ 0\\.037915161924059644\ \(0\)\
\-\ 99\\:\\ 0\\.03771397502380939\ \(0\)\
\-\ emboli\\:\\ 0\\.03771397502380939\ \(0\)\
\-\ multiple\\:\\ 0\\.03760680663250536\ \(0\)\
\-\ patient\\:\\ 0\\.03751092425143806\ \(0\)\
\-\ acquired\\:\\ 0\\.03705365951193181\ \(0\)\
\-\ bronchogenic\\:\\ 0\\.03696439647631329\ \(0\)\
\-\ murmurs\\:\\ 0\\.03687630031121343\ \(0\)\
\-\ primarily\\:\\ 0\\.03687630031121343\ \(0\)\
\-\ remains\\:\\ 0\\.03661871759513443\ \(0\)\
\-\ determined\\:\\ 0\\.03661871759513443\ \(0\)\
\-\ septic\\:\\ 0\\.036534998994763826\ \(0\)\
\-\ daily\\:\\ 0\\.03645230764241955\ \(0\)\
\-\ 64\\:\\ 0\\.03613132980537633\ \(0\)\
\-\ advanced\\:\\ 0\\.03613132980537633\ \(0\)\
\-\ testicular\\:\\ 0\\.036053418409728456\ \(0\)\
\-\ 66\\:\\ 0\\.036053418409728456\ \(0\)\
\-\ auscultation\\:\\ 0\\.035976397449526645\ \(0\)\
\-\ melanoma\\:\\ 0\\.03590024680128623\ \(0\)\
\-\ adults\\:\\ 0\\.03590024680128623\ \(0\)\
\-\ analysis\\:\\ 0\\.035750479289728465\ \(0\)\
\-\ smoking\\:\\ 0\\.03560396785295984\ \(0\)\
\-\ alcohol\\:\\ 0\\.03553188951172818\ \(0\)\
\-\ viral\\:\\ 0\\.03546057391857766\ \(0\)\
\-\ overall\\:\\ 0\\.03532016757624872\ \(0\)\
\-\ 41\\:\\ 0\\.0352510463481245\ \(0\)\
\-\ diabetes\\:\\ 0\\.035114895037398806\ \(0\)\
\-\ rounded\\:\\ 0\\.034981439970223266\ \(0\)\
\-\ which\\:\\ 0\\.034961006448685175\ \(0\)\
\-\ majority\\:\\ 0\\.03491569056418556\ \(0\)\
\-\ higher\\:\\ 0\\.03491569056418556\ \(0\)\
\-\ denied\\:\\ 0\\.03472220567696072\ \(0\)\
\-\ testing\\:\\ 0\\.03453412107903109\ \(0\)\
\-\ angiogram\\:\\ 0\\.03453412107903109\ \(0\)\
\-\ fungal\\:\\ 0\\.034411585691258455\ \(0\)\
\-\ fell\\:\\ 0\\.03423186142272717\ \(0\)\
\-\ granulomatous\\:\\ 0\\.03417300287686418\ \(0\)\
\-\ nature\\:\\ 0\\.033942578357377046\ \(0\)\
\-\ markedly\\:\\ 0\\.033942578357377046\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.03388618254154831\ \(0\)\
\-\ 33\\:\\ 0\\.03383025474618323\ \(0\)\
\-\ dyspnea\\:\\ 0\\.03383025474618323\ \(0\)\
\-\ states\\:\\ 0\\.033774787267109696\ \(0\)\
\-\ mg\\:\\ 0\\.0335573729073846\ \(0\)\
\-\ despite\\:\\ 0\\.03345124062475093\ \(0\)\
\-\ that\\:\\ 0\\.03336580983584824\ \(0\)\
\-\ regular\\:\\ 0\\.03319299980988094\ \(0\)\
\-\ having\\:\\ 0\\.03314251822055177\ \(0\)\
\-\ those\\:\\ 0\\.03289563124786362\ \(0\)\
\-\ ovarian\\:\\ 0\\.03275172697607151\ \(0\)\
\-\ by\\:\\ 0\\.032650420340954826\ \(0\)\
\-\ healthy\\:\\ 0\\.03261083137745982\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.032564513252429275\ \(0\)\
\-\ sarcoma\\:\\ 0\\.03224890491663714\ \(0\)\
\-\ is\\:\\ 0\\.03158379034089851\ \(0\)\
\-\ room\\:\\ 0\\.0314600302772572\ \(0\)\
\-\ via\\:\\ 0\\.03142096199008424\ \(0\)\
\-\ 17\\:\\ 0\\.03138211888160932\ \(0\)\
\-\ infectious\\:\\ 0\\.03093266832484071\ \(0\)\
\-\ ed\\:\\ 0\\.03075389761282515\ \(0\)\
\-\ neurologic\\:\\ 0\\.030718705571164802\ \(0\)\
\-\ condition\\:\\ 0\\.030718705571164802\ \(0\)\
\-\ nodular\\:\\ 0\\.030614218816719926\ \(0\)\
\-\ from\\:\\ 0\\.030536014404314086\ \(0\)\
\-\ ii\\:\\ 0\\.030310140442104134\ \(0\)\
\-\ increasing\\:\\ 0\\.0302771855565648\ \(0\)\
\-\ appear\\:\\ 0\\.0302771855565648\ \(0\)\
\-\ shown\\:\\ 0\\.029801275363671886\ \(0\)\
\-\ cells\\:\\ 0\\.029619939024647626\ \(0\)\
\-\ hypertension\\:\\ 0\\.0294143682950203\ \(0\)\
\-\ use\\:\\ 0\\.0294143682950203\ \(0\)\
\-\ an\\:\\ 0\\.029401097391816507\ \(0\)\
\-\ ct\\:\\ 0\\.029271370487331635\ \(0\)\
\-\ rate\\:\\ 0\\.029131164413058578\ \(0\)\
\-\ cysts\\:\\ 0\\.029131164413058578\ \(0\)\
\-\ at\\:\\ 0\\.02904096280271766\ \(0\)\
\-\ malignancy\\:\\ 0\\.028779941096631803\ \(0\)\
\-\ course\\:\\ 0\\.028396198318520017\ \(0\)\
\-\ lungs\\:\\ 0\\.02837137596757113\ \(0\)\
\-\ studies\\:\\ 0\\.028200133271254587\ \(0\)\
\-\ breast\\:\\ 0\\.02791633299454347\ \(0\)\
\-\ clear\\:\\ 0\\.027870173494471188\ \(0\)\
\-\ reported\\:\\ 0\\.02768863361082486\ \(0\)\
\-\ very\\:\\ 0\\.02757760538851801\ \(0\)\
\-\ including\\:\\ 0\\.027511855982480304\ \(0\)\
\-\ later\\:\\ 0\\.027511855982480304\ \(0\)\
\-\ risk\\:\\ 0\\.027468376730611074\ \(0\)\
\-\ otherwise\\:\\ 0\\.027403679331360235\ \(0\)\
\-\ status\\:\\ 0\\.026828026841021913\ \(0\)\
\-\ heart\\:\\ 0\\.026730212922740453\ \(0\)\
\-\ labs\\:\\ 0\\.026633798393288385\ \(0\)\
\-\ presentation\\:\\ 0\\.02646365374351826\ \(0\)\
\-\ left\\:\\ 0\\.0262276244705035\ \(0\)\
\-\ masses\\:\\ 0\\.02617139068224794\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.02617139068224794\ \(0\)\
\-\ inflammatory\\:\\ 0\\.025994960170084954\ \(0\)\
\-\ three\\:\\ 0\\.025806076807097234\ \(0\)\
\-\ type\\:\\ 0\\.025789165228175696\ \(0\)\
\-\ along\\:\\ 0\\.02575546885465618\ \(0\)\
\-\ cancer\\:\\ 0\\.02560588602844567\ \(0\)\
\-\ several\\:\\ 0\\.025222507183875365\ \(0\)\
\-\ air\\:\\ 0\\.025145309768592996\ \(0\)\
\-\ found\\:\\ 0\\.024874499467565207\ \(0\)\
\-\ any\\:\\ 0\\.024845070334931895\ \(0\)\
\-\ usually\\:\\ 0\\.024201415550115124\ \(0\)\
\-\ some\\:\\ 0\\.024188083675018134\ \(0\)\
\-\ enhancing\\:\\ 0\\.024082367614517427\ \(0\)\
\-\ renal\\:\\ 0\\.023939663789261212\ \(0\)\
\-\ treated\\:\\ 0\\.023939663789261212\ \(0\)\
\-\ decreased\\:\\ 0\\.023812504155204584\ \(0\)\
\-\ year\\:\\ 0\\.023694871588287026\ \(0\)\
\-\ pulmonary\\:\\ 0\\.023432899587033554\ \(0\)\
\-\ when\\:\\ 0\\.023221914196191025\ \(0\)\
\-\ following\\:\\ 0\\.02306226265353317\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0228953029834018\ \(0\)\
\-\ all\\:\\ 0\\.022884318041012496\ \(0\)\
\-\ include\\:\\ 0\\.022873350974859548\ \(0\)\
\-\ two\\:\\ 0\\.02282966031510198\ \(0\)\
\-\ chronic\\:\\ 0\\.02281878176445295\ \(0\)\
\-\ however\\:\\ 0\\.02275387666569068\ \(0\)\
\-\ been\\:\\ 0\\.02239744078196664\ \(0\)\
\-\ fluid\\:\\ 0\\.022196253881716376\ \(0\)\
\-\ significant\\:\\ 0\\.022196253881716376\ \(0\)\
\-\ due\\:\\ 0\\.022097868767039803\ \(0\)\
\-\ common\\:\\ 0\\.02180169484151496\ \(0\)\
\-\ who\\:\\ 0\\.021745844295370867\ \(0\)\
\-\ both\\:\\ 0\\.021437813714713694\ \(0\)\
\-\ metastatic\\:\\ 0\\.02108416932653705\ \(0\)\
\-\ acute\\:\\ 0\\.020796298689549336\ \(0\)\
\-\ increased\\:\\ 0\\.02078825181018885\ \(0\)\
\-\ imaging\\:\\ 0\\.020203199939446078\ \(0\)\
\-\ woman\\:\\ 0\\.020021341612104556\ \(0\)\
\-\ most\\:\\ 0\\.020007002754219287\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01992867977301966\ \(0\)\
\-\ were\\:\\ 0\\.01981635616182584\ \(0\)\
\-\ it\\:\\ 0\\.01967853416712752\ \(0\)\
\-\ have\\:\\ 0\\.01920448453486771\ \(0\)\
\-\ female\\:\\ 0\\.018550614668071896\ \(0\)\
\-\ presents\\:\\ 0\\.018493161117512678\ \(0\)\
\-\ treatment\\:\\ 0\\.018312533604090218\ \(0\)\
\-\ has\\:\\ 0\\.01755973130113263\ \(0\)\
\-\ normal\\:\\ 0\\.015696098715825165\ \(0\)\
\-\ are\\:\\ 0\\.014587444088043338\ \(0\)\
\-\ this\\:\\ 0\\.013209774081578068\ \(0\)\
\-\ for\\:\\ 0\\.011651837342645356\ \(0\)\
